智通财经APP获悉，上交所公布，截至10月31日，沪市上市公司完成2025年三季报披露。数据显示，随 着宏观政策发力显效，沪市上市公司顶住压力，经营业绩实现同比、环比双增，展现出良好的发展势 头。2025年前三季度，沪市上市公司合计实现营业收入37.58万亿元，同比微增；实现净利润3.79万亿 元，同比增长4.5%；扣非后净利润3.65万亿元，同比增长5.5%。 原文如下： 截至10月31日，沪市上市公司完成2025年三季报披露。数据显示，随着宏观政策发力显效，沪市上市公 司顶住压力，经营业绩实现同比、环比双增，展现出良好的发展势头。 一、三季度业绩增速喜人 2025年前三季度，沪市上市公司合计实现营业收入37.58万亿元，同比微增；实现净利润3.79万亿元，同 比增长4.5%；扣非后净利润3.65万亿元，同比增长5.5%。 分季度看，第三季度净利润、扣非后净利润同比分别增长11.4%、14.6%，较第二季度增速高出10.8个百 分点、14.3个百分点，环比分别增长16.9%、19.2%。业绩稳定增长下，一年多次分红渐成常态，累计 501家次公司推出中报、三季报分红方案，现金分红总额超6000亿元，同比增长3 ...

Core Viewpoint - The Shanghai Stock Exchange reports that listed companies in the Shanghai market have shown positive growth in their operating performance for the first three quarters of 2025, with both year-on-year and quarter-on-quarter increases in revenue and net profit, reflecting a robust development trend [1] Group 1: Q3 Performance Growth - In the first three quarters of 2025, listed companies in the Shanghai market achieved a total operating revenue of 37.58 trillion yuan, a slight year-on-year increase, and a net profit of 3.79 trillion yuan, representing a 4.5% year-on-year growth [2] - In Q3 alone, net profit and net profit after deducting non-recurring gains and losses increased by 11.4% and 14.6% year-on-year, respectively, with significant quarter-on-quarter growth of 16.9% and 19.2% [2] - A total of 501 companies announced dividend plans, with cash dividends exceeding 600 billion yuan, a 3.3% increase year-on-year [2] Group 2: Steady Growth of Private Enterprises - Private enterprises reported a year-on-year revenue growth of 4.5% and a net profit growth of 10.0% in the first three quarters [3] - The net profit growth rates for the first three quarters were 0.4%, 12.3%, and 17.2%, indicating a significant upward trend in Q3 [3] - The net cash flow from operating activities reached 2.37 trillion yuan, a 14.6% year-on-year increase, with the ratio of operating cash flow to net profit rising to 1.5 times [3] Group 3: New Momentum for Growth - High-tech industries are driving performance growth, with R&D investment in high-tech manufacturing services reaching 229.6 billion yuan, a 9% year-on-year increase [4] - The semiconductor industry saw net profits increase by 82% and 25% for chip design and semiconductor equipment, respectively [4] - Companies in the AI-driven sector, such as Cambricon and Haiguang Information, reported revenue growth of 24 times and 55%, respectively [4] Group 4: Breakthroughs in Key Technologies - In the biopharmaceutical sector, 26 new class 1 drugs were approved, including a globally innovative drug developed by He Yuan Bio [5] - The high-end equipment sector achieved breakthroughs in key areas, with significant advancements in machine tools and construction equipment [5] - In the communications field, GuoDun Quantum achieved mass production of the world's first four-channel ultra-low noise semiconductor single-photon detector [5] Group 5: New Consumption Potential - The smart home sector saw significant growth, with companies like Ecovacs and Haier reporting net profit increases of 131% and 15%, respectively [7] - The electric vehicle market experienced over 10% growth in sales, with SAIC Motor achieving record sales in September [8] - The food and beverage sector is tapping into new consumer demands, with Kweichow Moutai's high-end products seeing a 20% increase in sales revenue [8] Group 6: Resilience in Foreign Trade - Major ports in Shanghai, Ningbo, and Qingdao reported a total cargo throughput of 1.912 billion tons, a 5% year-on-year increase [12] - The export of new energy vehicles surged by 71% year-on-year, with leading companies like SAIC and GAC making significant gains [13] - The diversification of markets is strengthening, with Chinese companies expanding operations in Southeast Asia and the Middle East [14] Group 7: Accelerated Reform Measures - The implementation of the "Science and Technology Innovation Board 1+6" reforms has led to 18 new IPO applications, including four from unprofitable companies [15] - The number of asset restructuring cases in the Shanghai market reached 602, with a significant increase in major asset restructurings [16] - The reforms are enhancing the valuation and performance commitments of companies involved in mergers and acquisitions [16]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 InnoCare Pharma Limited 於本公告日期，董事會包括主席兼執行董事崔霽松博士；執行董事趙仁濱博士；非執行董事 施一公博士及謝榕剛先生；以及獨立非執行董事胡蘭女士、董丹丹博士及管坤良教授。 （股份代號：9969） 董事會召開日期 諾誠健華醫藥有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公司將於 2025年11月13日（星期四）舉行董事會會議，藉以（其中包括）考慮及批准本公司 及其附屬公司截至2025年9月30日止九個月之未經審核第三季度業績及其發佈。 承董事會命 諾誠健華醫藥有限公司 主席兼執行董事 崔霽松博士 香港，2025年10月31日 諾誠健華醫藥有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） ...

Core Viewpoint - The company, Innovent Biologics (09969.HK), has announced that it will hold a board meeting on November 13, 2025, to consider and approve its unaudited third-quarter results for the nine months ending September 30, 2025 [1] Group 1 - The board meeting is scheduled for November 13, 2025 [1] - The meeting will focus on the approval of the company's unaudited third-quarter performance [1] - The performance period under review is for the nine months ending September 30, 2025 [1]

Core Viewpoint - The recent advancements in innovative pharmaceuticals within the Future Science City Life Valley highlight significant progress in drug development, particularly in the fields of antibody-drug conjugates, gene therapy, and personalized cancer vaccines, indicating a strong potential for new treatment options in oncology and ophthalmology [1][2][3]. Group 1: Innovative Drug Developments - The innovative ADC drug ICP-B794 developed by the company Nocare has completed its first patient dosing, targeting the B7-H3 protein, which is highly expressed in various solid tumors, potentially filling a treatment gap [1]. - The ADC platform utilized by Nocare is designed to precisely target tumor cells, reducing off-target effects and offering hope for patients with lung, esophageal, nasopharyngeal, and prostate cancers [1]. Group 2: Gene Therapy Progress - The gene therapy drug GA001 developed by Jianda has received Fast Track designation from the FDA, expediting its clinical trial and registration process [2]. - GA001 has shown significant results in treating late-stage blindness caused by retinitis pigmentosa, with most trial participants experiencing notable vision improvement since the first dosing in January 2024 [2]. Group 3: Personalized Cancer Vaccines - The mRNA personalized cancer vaccine XH001 developed by New Harmony has initiated Phase I clinical trials, marking it as the first of its kind in China and lacking global market equivalents [3]. - The clinical study aims to evaluate the safety, tolerability, and preliminary efficacy of XH001 in high-risk recurrent solid tumor patients post-surgery, utilizing a proprietary platform to select the most immunogenic new antigens [3].

Core Viewpoint - The company, Innovent Biologics (09969.HK), has announced that it will hold a board meeting on November 13, 2025, to consider and approve its unaudited third-quarter results for the nine months ending September 30, 2025 [1] Summary by Category - **Company Announcement** - Innovent Biologics will conduct a board meeting on November 13, 2025, to review and approve its financial results [1] - The meeting will focus on the unaudited third-quarter performance for the period ending September 30, 2025 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：9969） 董事會召開日期 諾誠健華醫藥有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公司將於 2025年11月13日（星期四）舉行董事會會議，藉以（其中包括）考慮及批准本公司 及其附屬公司截至2025年9月30日止九個月之未經審核第三季度業績及其發佈。 InnoCare Pharma Limited 諾誠健華醫藥有限公司 於本公告日期，董事會包括主席兼執行董事崔霽松博士；執行董事趙仁濱博士；非執行董事 施一公博士及謝榕剛先生；以及獨立非執行董事胡蘭女士、董丹丹博士及管坤良教授。 承董事會命 諾誠健華醫藥有限公司 主席兼執行董事 崔霽松博士 香港，2025年10月31日 ...

Group 1 - The pharmaceutical sector has been experiencing fluctuations since September, following a strong rally, and is currently undergoing a rotation adjustment. The question arises whether the sector is worth attention after a valuation decline and if there is still growth logic [1] - The fundamentals supporting the innovative drug sector may continue to strengthen in Q4, with multiple catalysts on the horizon that could further release industrial development momentum [1] Group 2 - The policy environment for the pharmaceutical industry is improving, with the National Healthcare Security Administration and the National Health Commission jointly releasing measures to support high-quality development of innovative drugs, providing comprehensive support across five key areas [2][4] - The implementation of ICH guidelines in China is promoting more efficient and scientific drug evaluation processes, enhancing regulatory confidence [2] Group 3 - The upcoming peak season for business development (BD) transactions is expected to see increased activity, with historical data indicating that October and November are high-frequency periods for such transactions [5] - A significant deal was struck on October 8, with Innovent Biologics making a $100 million upfront payment, marking the beginning of Q4's BD activity [5] - On October 22, Innovent Biologics and Takeda Pharmaceuticals announced a global strategic collaboration worth up to $11.4 billion, setting a record for BD transaction amounts among Chinese innovative drug companies [6] Group 4 - The valuation of the pharmaceutical sector shows a significant gap from its recent five-year price peak, indicating potential for recovery [9] - The proportion of public equity funds heavily invested in the pharmaceutical sector has increased to 12.2%, suggesting that there is still room for growth compared to the historical average of 13.7% [9] - Excluding pharmaceutical-themed funds, the proportion of public equity funds in the sector is at a historical low of 6.44%, indicating potential for significant inflow of new capital if market interest increases [9] Group 5 - For ordinary investors, investing in individual innovative drug stocks poses challenges due to the need for specialized tracking capabilities across various aspects such as pipelines, clinical trials, and regulations. Therefore, considering ETFs that cover industry leaders may be a more effective strategy [10]

Group 1 - The core viewpoint of the news highlights a significant increase in the performance of innovative drug ETFs, driven by improved geopolitical relations between China and the U.S. and the onset of the fourth quarter's business development (BD) peak season for innovative drugs [1][3] - Multiple innovative drug ETFs, including those from Huatai-PineBridge, ICBC, and others, have seen gains exceeding 5%, indicating a positive market sentiment towards the sector [1] - The recent U.S.-China summit has alleviated previous geopolitical concerns, leading to a rapid recovery in market expectations for innovative drugs [1] Group 2 - Pfizer has registered two global Phase III clinical trials for its PD-1/VEGF dual antibody PF-08634404, targeting advanced non-small cell lung cancer and metastatic colorectal cancer, with significant patient enrollment planned [2] - The trials are set to compare the new treatment against established therapies, with completion dates projected for early 2029 and 2030, respectively [2] - Pfizer's collaboration with 3SBio involves a substantial upfront payment and milestone payments, indicating strong financial backing for the development of this dual antibody [2] Group 3 - The fourth quarter is marked by several catalysts for the innovative drug sector, including major academic conferences and a peak in BD transactions, which are expected to enhance market activity [3] - Chinese innovative drug companies are gaining recognition on international platforms, with key products selected for late-breaking abstracts at major conferences, showcasing their R&D capabilities [3] - The domestic policy environment is favorable for innovative drugs, with clear support for genuine innovation and an expected adjustment in the medical insurance catalog [3] Group 4 - By 2025, China is projected to become a significant player in the global innovative drug market, with patent authorization transactions expected to exceed $100 billion, reflecting a 170% year-on-year increase [4] - The proportion of patent authorizations in the U.S. from Chinese companies has risen from 5% in 2019 to 24%, positioning China as a major source of innovative drug patents outside the U.S. [4] - The upcoming ESMO conference is anticipated to showcase the growth and international influence of Chinese research, marking a transition from a follower to a leader in the innovative drug space [4]

Core Insights - Nuo Cheng Jian Hua's stock increased by 5.09% to 23.96 CNY per share, with a total market capitalization of 42.281 billion CNY as of October 31 [1] Company Overview - Nuo Cheng Jian Hua Pharmaceutical Co., Ltd. is based in Beijing and was established on November 3, 2015, with its IPO on September 21, 2022 [1] - The company focuses on the research, production, and commercialization of biopharmaceuticals, particularly in oncology and autoimmune diseases [1] - The revenue composition includes 87.67% from drug sales, 12.04% from technology licensing, and 0.15% each from testing and R&D services [1] Fund Holdings - Jianxin Fund has a significant position in Nuo Cheng Jian Hua, with its Jianxin High-end Medical Stock A fund holding 147,800 shares, representing 3.39% of the fund's net value [2] - The fund has generated an estimated floating profit of approximately 171,500 CNY today [2] Fund Manager Information - The fund manager of Jianxin High-end Medical Stock A is Pan Longling, who has been in the position for 9 years and 218 days [3] - The fund's total asset size is 162 million CNY, with a best return of 48.64% and a worst return of -31% during the manager's tenure [3]